 Fate Therapeutics Inc NASDAQ: FATE has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed refractory B-cell lymphoma. Data were presented at the 2021 American Society of Clinical Oncology ASCO Annual Meeting. 